Novel use of clinical pathways to improve clinical trial accrual.

• DOI: 10.1200/op.2024.20.10_suppl.414
• Publication Date: 2024-09-30T13:33:33Z
• Authors: Joanna Addonizio; Alex Post; Matthew Rice; Carly Powell; Sunyi Zhang; Trang N. Nguyen; Hao-Yu Chang; Shruti Gupta; Erica Fox; David Michael Jac...

414 Background: Fewer than 10% of adult cancer patients participate in clinical trials. Clinical pathways platforms have traditionally sought to improve trial accrual by displaying available trials for eligible patients. Our team explored how Pathways navigation data can also be used identify poorly accruing and provide study investigators with a near real-time feed those Methods: Providers at Dana-Farber Cancer Institute are asked navigate the decision-support platform order systemic therapies 7 days advance administration assist authorization. We invited Principal Investigators (PIs) collaborate our through Accrual Trials (PACT) service. Through PACT, PIs informed who were navigated nodes involving question but received standard therapy instead. given access Tableau Dashboard that is updated new daily receive weekly reminders about dashboard. The current analysis includes two been using PACT least one year. reviewed monthly rates from time opening until March 2024. dataset did not meet criteria Poisson analysis, so Fischer’s exact test was compare rates. ensured denominator potentially relatively consistent. Results: DF-21-519 accrued 16 over 14 months prior 33 12 PACT. DF-22-028 0 6 Collectively, use more doubled involved (one-tailed p = 0.048). Conclusions: A appropriate resources. Here, we show program helped double studies. Scaling this technology across broader swath could an important participation users platform. Trial Accruals, Pre Rate, (Accruals/month) Post accruals mo 1.14 2.75 0.86 Total 20 0.8 45 26 1.73 one-tailed 0.048